TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FA2H drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Standard (Lysate) | FA2H Full-Length Lysate Standard; HEK293 expressed, Theoretical MW verified, High Purity (>95%). | View FA2H Products |
| Recombinant Protein | FA2H Recombinant Protein (Catalytic Domain / Disease Mutant); High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. | View FA2H Products |
| Gene Delivery | FA2H Lentivirus Particles; Full-length ORF for stable cell line generation. HEK293T packaged, Sequence Verified, Endotoxin <1EU/ug. | View FA2H Products |
| Benchmark Antibody | Anti-FA2H Recombinant Rabbit mAb; Sequence-verified positive control for western blot and assay normalization. | View FA2H Products |
| Validator | FA2H siRNA Set; For knockdown verification and specificity controls. Sequence Verified. | View FA2H Products |
| Related Target: SPTLC1 | Serine palmitoyltransferase, rate-limiting enzyme in de novo sphingolipid synthesis pathway. | View SPTLC1 Products |
| Related Target: SPTLC2 | Upstream serine palmitoyltransferase, rate-limiting in de novo sphingolipid synthesis. | View SPTLC2 Products |
| Related Target: CERS2 | Ceramide synthase 2, downstream enzyme utilizing FA2H products for myelinating glia. | View CERS2 Products |
| Related Target: SPHK1 | Sphingosine kinase, synergistic target in sphingolipid metabolism pathway. | View SPHK1 Products |
| Related Target: UGCG | Glucosylceramide synthase, downstream ceramide utilization control. | View UGCG Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER Membrane Integrity & Topology | Full-length FA2H Lentivirus retains native ER insertion signals and cytochrome b5 reductase coupling domains; Sequence Verified ORFs ensure native ER-targeting signal integrity. |
| Enzymatic Activity (2-Hydroxylation) | Stable cell lines compatible with Mass Spec-based lipidomics; HEK293-expressed recombinant FA2H (>95% purity) for functional biochemical assays preserving di-iron center. |
| Specificity vs. Other Fatty Acid Hydroxylases | RNAi validators (siRNA) with sequence-verified targeting for orthogonal confirmation; validated siRNA set included. |
| Disease Mutant Mechanism Studies | Recombinant FA2H disease-associated mutants (e.g., SPG35 mutations) available, Sequence Verified. |
| Lack of Clinical Benchmark Controls | High-purity recombinant standards and recombinant benchmark antibody for assay calibration in rare disease indication. |
Live FA2H R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
FA2H (fatty acid 2-hydroxylase) is a key enzyme for 2-hydroxysphingolipid synthesis in myelin maintenance. Therapeutic targeting is an emerging frontier, primarily focused on rare neurodegenerative disorders such as Fatty Acid Hydroxylase-Associated Neurodegeneration (FAHN) and Hereditary Spastic Paraplegia type 35 (SPG35) associated with leukodystrophy. The current pipeline is predominantly preclinical, led by academic research centers and rare disease biotechs exploring gene therapy vectors and small-molecule chaperones. Concurrently, FA2H is gaining attention in immuno-oncology due to its role in tumor microenvironment lipid remodeling, with selective small-molecule inhibitors being explored for solid tumors. The next wave of R&D is expected to target genetic restoration for leukodystrophy and specific enzyme inhibition in cancer, leveraging lipidomics-compatible assays and high-purity reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic consortia, Rare Disease Biotechs, Gene Therapy Innovation Labs | FAHN, SPG35, Leukodystrophy | Cell-based functional rescue assays requiring stable FA2H expression (Lentivirus ORF vectors) and expression validation (specific Abs) |
| Small Molecule Inhibitors | Oncology pipelines, Academic Consortia | Solid Tumors, Neurodegeneration | Enzymatic assays with high-purity recombinant WT and mutant FA2H; also need membrane-bound protein for activity |
| Small Molecule Chaperones | Early discovery programs, Rare Disease Discovery Biotechs | Neurodegeneration | Enzymatic activity assays with full-length membrane-bound protein |
| siRNA/ASO (Genetic Modulation) | Neuroscience Research Institutes, Lipid Metabolism Companies | FA2H-related Leukodystrophy, Metabolic Disorders | Knockdown verification (need validated FA2H siRNA and benchmark antibody) |
| Substrate Modulation | Lipid metabolism specialists | Demyelinating diseases | Lipidomics-compatible stable cell lines for sphingolipid analysis |
(Note: Product links are placeholders for TarMart catalog entries.)